GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was £7.53B, up 17.6% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is £7.53B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £7.53B | +17.6% |
| FY2024 | Dec 31, 2024 | £6.40B | +2.9% |
| FY2023 | Dec 31, 2023 | £6.22B | +13.4% |
| FY2022 | Dec 31, 2022 | £5.49B | +9.3% |
| FY2021 | Dec 31, 2021 | £5.02B | +4.7% |
| FY2020 | Dec 31, 2020 | £4.79B | +4.9% |
| FY2019 | Dec 31, 2019 | £4.57B | +17.3% |
| FY2018 | Dec 31, 2018 | £3.89B | -13.0% |
| FY2017 | Dec 31, 2017 | £4.48B | +23.4% |
| FY2016 | Dec 31, 2016 | £3.63B | +1.9% |
| FY2015 | Dec 31, 2015 | £3.56B | – |